1. Yates JW, Wallace Jr HJ, Ellison RR, Holland JF. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. 1973;57(4):485–8.
2. Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127(1):53–61. doi: 10.1182/blood-2015-08-604520 .
3. Weil M, Glidewell OJ, Jacquillat C, Levy R, Serpick AA, Wiernik PH, et al. Daunorubicin in the therapy of acute granulocytic leukemia. Cancer Res. 1973;33(5):921–8.
4. Lichtman MA. A historical perspective on the development of the cytarabine (7 days) and daunorubicin (3 days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7 + 3. Blood Cells Mol Dis. 2013;50(2):119–30. doi: 10.1016/j.bcmd.2012.10.005 .
5. Bernard J, Jacquillat C, Boiron M, Najean Y, Seligmann M, Tanzer J, et al. Trial of treatment of acute lymphoblastic and myeloblastic leukemias by a new antibiotic: rubidomycin (RP 13,057). Study of 61 cases. Presse Med. 1967;75(19):951–5.